Presentations
IARPD 2022 Poster - Setting the TEMPO: A Phase 3 Program to Investigate Tavapadon, a Selective D1/D5 Partial Agonist, for Parkinson’s Disease
May 13, 2022
1Q 2022 Financial Results & Business Update
May 10, 2022
SIRS 2022 Presentation – Emraclidine as a Novel Positive Allosteric Modulator Targeting M4 Muscarinic Receptors: Results From a Phase 1b Trial in Patients With Schizophrenia
Apr 08, 2022
AAN 2022 Poster - Levodopa and Dopamine Agonist Medication Utilization among Patients with Parkinson’s Disease Enrolled in Commercial and Medicare Advantage Part D Health Plans
Apr 05, 2022
AAN 2022 Presentation - Darigabat: pronounced antiepileptic activity in the mesial temporal lobe mouse model of drug-resistant focal epilepsy
Apr 05, 2022
AAN 2022 Poster - Ensuring the Continuity of Data Collection in a Focal Epilepsy Clinical Trial During the COVID-19 Pandemic
Apr 05, 2022
AAN 2022 Poster - Pharmacokinetics, Pharmacodynamics, and Safety of the Highly Selective Dopamine D1/D5 Agonist Tavapadon: Summary of Early Phase Clinical Studies
Apr 05, 2022
4Q 2021 Financial Results & Business Update
Mar 01, 2022
Topline Results for Darigabat in Phase 1 Acute Anxiety Clinical Trial Presentation
Feb 15, 2022
J.P. Morgan Healthcare Conference Presentation
Jan 10, 2022